Nuveen Asset Management LLC decreased its holdings in shares of DaVita Inc. (NYSE:DVA) by 31.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 251,860 shares of the company’s stock after selling 117,829 shares during the period. Nuveen Asset Management LLC’s holdings in DaVita were worth $27,143,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Bessemer Group Inc. lifted its stake in DaVita by 72.5% during the first quarter. Bessemer Group Inc. now owns 307 shares of the company’s stock valued at $33,000 after buying an additional 129 shares in the last quarter. First Horizon Advisors Inc. lifted its stake in DaVita by 133.8% during the first quarter. First Horizon Advisors Inc. now owns 346 shares of the company’s stock valued at $36,000 after buying an additional 198 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its stake in DaVita by 29.8% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 623 shares of the company’s stock valued at $67,000 after buying an additional 143 shares in the last quarter. CSat Investment Advisory L.P. lifted its stake in DaVita by 43.3% during the first quarter. CSat Investment Advisory L.P. now owns 967 shares of the company’s stock valued at $104,000 after buying an additional 292 shares in the last quarter. Finally, E Fund Management Co. Ltd. purchased a new stake in DaVita during the first quarter valued at about $108,000. Institutional investors own 88.22% of the company’s stock.
A number of research firms have commented on DVA. Bank of America reaffirmed an “underperform” rating and set a $118.00 price objective (down from $127.00) on shares of DaVita in a research note on Thursday, April 1st. Deutsche Bank Aktiengesellschaft upped their price objective on shares of DaVita from $150.00 to $207.00 and gave the company a “buy” rating in a research note on Monday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. DaVita presently has an average rating of “Hold” and an average price target of $134.40.
DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, April 29th. The company reported $2.09 EPS for the quarter, beating the consensus estimate of $1.80 by $0.29. DaVita had a return on equity of 50.57% and a net margin of 6.69%. The company had revenue of $2.82 billion for the quarter, compared to the consensus estimate of $2.83 billion. As a group, research analysts expect that DaVita Inc. will post 8.9 EPS for the current year.
In other news, CEO Javier Rodriguez sold 27,053 shares of the firm’s stock in a transaction on Wednesday, May 5th. The shares were sold at an average price of $122.22, for a total value of $3,306,417.66. Following the sale, the chief executive officer now owns 397,716 shares in the company, valued at $48,608,849.52. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kathleen Alyce Waters sold 5,290 shares of the firm’s stock in a transaction on Monday, May 3rd. The stock was sold at an average price of $118.36, for a total transaction of $626,124.40. Following the completion of the sale, the insider now owns 97,694 shares in the company, valued at approximately $11,563,061.84. The disclosure for this sale can be found here. In the last quarter, insiders have sold 41,562 shares of company stock worth $5,078,119. Corporate insiders own 1.00% of the company’s stock.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading: Are 12b-1 Fees Affecting Your Mutual Fund Performance?
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.